TheStreet downgraded shares of Natera (NASDAQ:NTRA) from a c- rating to a d+ rating in a research note published on Tuesday.

A number of other research firms also recently issued reports on NTRA. BidaskClub downgraded shares of Natera from a strong-buy rating to a buy rating in a report on Thursday, August 30th. Zacks Investment Research downgraded shares of Natera from a buy rating to a hold rating in a report on Tuesday, August 14th. Canaccord Genuity boosted their price target on shares of Natera from $25.00 to $29.00 and gave the stock a buy rating in a research note on Thursday, August 16th. Craig Hallum boosted their price target on shares of Natera from $23.00 to $30.00 and gave the stock a buy rating in a research note on Thursday, August 9th. Finally, Piper Jaffray Companies boosted their price target on shares of Natera to $27.00 and gave the stock an overweight rating in a research note on Thursday, August 9th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of Buy and an average target price of $26.13.

NASDAQ NTRA opened at $20.77 on Tuesday. Natera has a 52-week low of $8.60 and a 52-week high of $29.62. The company has a quick ratio of 1.56, a current ratio of 1.69 and a debt-to-equity ratio of -3.32. The firm has a market cap of $1.46 billion, a PE ratio of -8.70 and a beta of 2.24.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Wednesday, August 8th. The medical research company reported ($0.55) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.55). Natera had a negative net margin of 59.07% and a negative return on equity of 752.93%. The company had revenue of $63.07 million during the quarter, compared to the consensus estimate of $61.71 million. During the same period in the previous year, the firm posted ($0.55) EPS. The firm’s revenue was up 20.6% compared to the same quarter last year. On average, equities analysts expect that Natera will post -2.07 EPS for the current year.

In other Natera news, COO Steven Leonard Chapman sold 45,000 shares of the business’s stock in a transaction on Tuesday, September 11th. The shares were sold at an average price of $25.16, for a total value of $1,132,200.00. Following the completion of the sale, the chief operating officer now directly owns 16,628 shares of the company’s stock, valued at $418,360.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Matthew Rabinowitz sold 185,163 shares of the business’s stock in a transaction on Tuesday, September 11th. The stock was sold at an average price of $25.13, for a total transaction of $4,653,146.19. Following the completion of the sale, the chief executive officer now directly owns 1,701,686 shares of the company’s stock, valued at $42,763,369.18. The disclosure for this sale can be found here. Insiders sold 1,813,321 shares of company stock valued at $44,508,270 over the last three months. 13.18% of the stock is currently owned by insiders.

Hedge funds have recently added to or reduced their stakes in the business. A.R.T. Advisors LLC purchased a new position in shares of Natera in the first quarter valued at about $164,000. State Board of Administration of Florida Retirement System purchased a new position in shares of Natera in the second quarter valued at about $200,000. Paradigm Capital Management Inc. NY purchased a new position in shares of Natera in the second quarter valued at about $207,000. Cubist Systematic Strategies LLC purchased a new position in shares of Natera in the second quarter valued at about $252,000. Finally, Woodmont Investment Counsel LLC purchased a new position in shares of Natera in the second quarter valued at about $258,000. Hedge funds and other institutional investors own 66.31% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Further Reading: What is a put option?

Analyst Recommendations for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.